PRT for Adolescents With High Functioning Autism
Launched by STANFORD UNIVERSITY · Aug 3, 2023
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
The clinical trial titled "PRT for Adolescents With High Functioning Autism" is investigating how a treatment called Pivotal Response Treatment (PRT) can help improve social and behavioral skills in highly verbal adolescents with autism spectrum disorder (ASD). The study will also look at changes in brain function after the treatment. This trial is currently recruiting participants, specifically adolescents aged 12 to 18 years who live in the San Francisco Bay Area and have a clinical diagnosis of high-functioning autism.
To be eligible for the trial, participants need to have an IQ above 80, be right-handed, and have no metal in their body (like braces). They also need to be willing to attend weekly treatment sessions for 9 weeks and show interest in improving their social skills. Before joining the study, they must have stable treatment plans in place for at least a month. Participants will undergo assessments to understand their social skills and may have MRI scans as part of the study. If you know an adolescent who meets these criteria and is looking to improve their social abilities, they might be a good fit for this trial.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Clinical Diagnosis of Autism Spectrum Disorder, higher functioning/low support needs
- • Intelligence Quotient (IQ): Participants with a Full Scale IQ \> 80 on the Wechsler Abbreviated Scale of Intelligence (WASI-II)
- • Right-handed
- • No metal in their body/unremovable metal on their body (i.e., braces)
- • First language is English
- • Must live in the San Francisco Bay Area
- • Able and willing to receive intervention weekly for 9 weeks
- • Adolescent is interested in improving their social skills
- • MRI Compatibility: No major contraindication for MRI.
- • Diagnosis of ASD using ADOS-2 and ADI-R.
- • No evidence of a genetic, metabolic, or infectious etiology for their autism.
- • Primary diagnosis of ASD
- • No evidence of significant difficulty during pregnancy, labor, delivery, or immediate neonatal period.
- • Stable treatment (e.g., ABA), speech therapy, school placement, psychotropic medication(s) or biomedical intervention(s) for at least 1 month prior to baseline measurements with no anticipated changes during study participation.
- • Score of at least 50% or below on at least 4 out of the 9 social target areas in the SLO (administered during pre-measures)
- • No evidence of significant difficulty during pregnancy, labor, delivery, or immediate neonatal period.
- Exclusion Criteria:
- • History of claustrophobia, previous head injury, serious neurological or medical illness, birth weight less than 4 lb. and/or gestational age \< 34 weeks
- • Left-handed
- • Braces or any metal in their body
About Stanford University
Stanford University is a prestigious academic institution renowned for its cutting-edge research and innovation in healthcare and medicine. As a clinical trial sponsor, Stanford leverages its extensive resources, including a collaborative network of world-class researchers and state-of-the-art facilities, to advance medical knowledge and improve patient care. The university is committed to conducting rigorous, ethical research that adheres to the highest standards of scientific integrity, fostering an environment where groundbreaking discoveries can translate into effective clinical applications. Through its clinical trials, Stanford aims to address critical health challenges and contribute to the development of novel therapies and treatment strategies.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Palo Alto, California, United States
Patients applied
Trial Officials
Dani A Abrams, Ph.D.
Principal Investigator
Stanford University
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported